What is the recommended management for lymphocytic colitis?

Management of Lymphocytic Colitis

Budesonide 9 mg daily for 6-8 weeks is the first-line treatment for symptomatic lymphocytic colitis, with patients more than twice as likely to achieve clinical remission compared to no treatment. 1

First-Line Therapy: Budesonide

• Budesonide 9 mg once daily is strongly recommended over all other treatments for inducing clinical remission in symptomatic lymphocytic colitis 1
• Patients treated with budesonide are 2.5 times more likely to achieve clinical remission within 7-13 days compared to placebo (RR 2.52,95% CI 1.45-4.4) 1
• Budesonide achieves both clinical response (88% vs 38% placebo) and histological response (78% vs 33% placebo) 2
• Budesonide is superior to mesalamine, with nearly twice the likelihood of achieving clinical and histological remission, making it the preferred choice when both options are available 1
• The once-daily dosing and favorable safety profile make budesonide highly practical for this typically older patient population 1

Second-Line Options (When Budesonide Not Feasible)

Mesalamine

• Mesalamine 2.4-3 g daily is the preferred alternative when budesonide is contraindicated, not tolerated, or patient preference dictates against it 1
• Clinical response rates of approximately 85% have been observed 2
• Cost is similar to budesonide, so expense is not a differentiating factor 1

Bismuth Subsalicylate

• Eight to nine 262 mg tablets daily (divided three times daily) for 8 weeks can be considered as another alternative 1
• The significant pill burden (8-9 tablets daily) is a major practical limitation in elderly patients taking multiple medications 1
• Evidence quality is low due to very small trial sizes 2
• Older patients may respond better to bismuth subsalicylate therapy 3

Prednisolone/Prednisone

• Consider when budesonide cost is prohibitive, as prednisolone is considerably less expensive 1
• This is a conditional recommendation based on very low quality evidence 1

Beclometasone Dipropionate

• Beclometasone dipropionate (5-10 mg/day) shows similar efficacy to mesalamine with 84% achieving clinical remission at 8 weeks 2
• However, remission is poorly maintained at 12 months (only 26% remain in remission) 2

Therapies NOT Recommended

• Combination mesalamine plus cholestyramine offers no advantage over mesalamine alone (85% vs 86% response rates) 1, 2
• Probiotics are not recommended due to uncertain benefit-to-harm balance 1
• Boswellia serrata is not recommended 1

Maintenance Therapy

• For patients who relapse after stopping induction therapy, budesonide 6 mg daily is strongly recommended for maintenance 1
• Maintenance budesonide reduces clinical relapse risk by 66% (RR 0.34,95% CI 0.19-0.6) over 6 months 1
• Lower doses (3 mg alternating with 6 mg daily) over 12 months show similar efficacy 1
• Important caveat: Only offer maintenance therapy to patients who have actually relapsed after stopping induction therapy—up to one-third may not require it 1
• Taper to the lowest effective dose in clinical practice 1
• Consider cessation after 6-12 months 1
• Monitor for bone loss with prolonged use and implement osteoporosis prevention and screening 1

Symptomatic Management

• Antidiarrheal agents like loperamide may be sufficient for patients with mild symptoms 4
• These can be used as adjunctive therapy alongside definitive treatment 5

Monitoring Considerations

• Colonoscopy to assess histological response is generally not necessary 1
• However, if symptoms persist after budesonide treatment, normal colonic biopsies may suggest coexisting conditions (such as celiac disease) that should be excluded 1